MAbSilico
Created in 2017
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
2,723 4,998Activities
Technologies
Entity types
Location
37000 Tours, France
Tours
France
Employees
Scale: 11-50
Estimated: 13
SIREN
832200224Engaged corporates
18
5 11Added in Motherbase
6 years, 5 months ago
deeptech Value proposition
The only TechBio providing computationally designed antibodies through AI with biological validations associated
MAbSilico is a TechBio company developing and providing AI-based solutions for antibody drug design and discovery.
We help biotech and pharma companies to leverage antibody discovery risks by providing computational candidates in days which are designed and characterized in silico and validated with state-of-the-art biological technologies.
While MAbSilico combines 3D modeling, interaction simulation and linear sequences analysis, the antibody drug candidates are defined through their epitope, affinity, off-target risk, cross-species reactivity and developability assessment to be ready for biological activity evaluation.
Using NLP technologies we gather information about antibodies and their target in different databases to ensure competitive landscape analysis and the freedom to operate of the computationally designed antibodies candidates.
Biotechnology, Therapeutic antibody, Antibody, Protein interaction, Epitope mapping, AI, Computation, HPC , in silico, Antibody design, and Protein designOriginal language
The only TechBio providing computationally designed antibodies through AI with biological validations associated
MAbSilico is a TechBio company developing and providing AI-based solutions for antibody drug design and discovery.
We help biotech and pharma companies to leverage antibody discovery risks by providing computational candidates in days which are designed and characterized in silico and validated with state-of-the-art biological technologies.
While MAbSilico combines 3D modeling, interaction simulation and linear sequences analysis, the antibody drug candidates are defined through their epitope, affinity, off-target risk, cross-species reactivity and developability assessment to be ready for biological activity evaluation.
Using NLP technologies we gather information about antibodies and their target in different databases to ensure competitive landscape analysis and the freedom to operate of the computationally designed antibodies candidates.
MAbSilico - Home
MAbSilico the best Antibody designing company, based in France. Get your design antibody in 21 days only.
https://www.mabsilico.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Technopole d'Orléans Business Consulting and Services | Technopole d'Orléans Business Consulting and Services | Other 13 Nov 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 11 Dec 2024 | | |
 Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Other 4 Jun 2024 | | |
 AbbVie Pharmaceutical, Pharmaceutical Manufacturing | AbbVie Pharmaceutical, Pharmaceutical Manufacturing | Other 3 Mar 2024 | | |
 CNRS Innovation Research, Research Services | CNRS Innovation Research, Research Services | Other 19 Jan 2024 | | |
 Novo Nordisk Pharmaceutical, Pharmaceutical Manufacturing | Novo Nordisk Pharmaceutical, Pharmaceutical Manufacturing | Other 26 Apr 2023 | | |
 Tours Métropole Val de Loire Government Administration, French metropolis | Tours Métropole Val de Loire Government Administration, French metropolis | Other 8 Feb 2023 | | |
 Dia & Co Semiconductors, Retail Apparel and Fashion | Dia & Co Semiconductors, Retail Apparel and Fashion | Other 21 Nov 2023 | | |
 Amgen Biotechnology, Biotechnology Research | Amgen Biotechnology, Biotechnology Research | Other 31 Jul 2022 | | |
 Institut Curie Health, Hospitals and Health Care | Institut Curie Health, Hospitals and Health Care | Other 8 Apr 2019 | | |